These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 26195323)

  • 1. TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium.
    Bruno A; Alentorn A; Daniau M; Labussière M; Rahimian A; Tabouret E; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Chrétien F; Eimer S; Houillier C; Soussain C; Mokhtari K; Hoang-Xuan K
    Acta Neuropathol; 2015 Sep; 130(3):439-40. PubMed ID: 26195323
    [No Abstract]   [Full Text] [Related]  

  • 2. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
    Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
    Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter mutations in primary and secondary glioblastomas.
    Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
    Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of NAB2-STAT6 fusion variants and TERT promotor mutations in solitary fibrous tumors/hemangiopericytomas of the CNS: not (yet) clear.
    Vogels R; Macagno N; Griewank K; Groenen P; Verdijk M; Fonville J; Kusters B; ; ; Figarella-Branger D; Wesseling P; Bouvier C; Flucke U
    Acta Neuropathol; 2019 Apr; 137(4):679-682. PubMed ID: 30761420
    [No Abstract]   [Full Text] [Related]  

  • 5. Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma.
    Montesinos-Rongen M; Schäfer E; Siebert R; Deckert M
    Acta Neuropathol; 2012 Dec; 124(6):905-6. PubMed ID: 23138649
    [No Abstract]   [Full Text] [Related]  

  • 6. Water diffusivity: comparison of primary CNS lymphoma and astrocytic tumor infiltrating the corpus callosum.
    Horger M; Fenchel M; Nägele T; Moehle R; Claussen CD; Beschorner R; Ernemann U
    AJR Am J Roentgenol; 2009 Nov; 193(5):1384-7. PubMed ID: 19843757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma.
    Pellissery S; Richter J; Haake A; Montesinos-Rongen M; Deckert M; Siebert R
    Leuk Lymphoma; 2010 Nov; 51(11):2135-6. PubMed ID: 20858097
    [No Abstract]   [Full Text] [Related]  

  • 8. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
    Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
    Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-grade central nervous system lymphoma: clarity through a hazy lens.
    Hauser SL
    Ann Neurol; 2006 May; 59(5):9A-10A. PubMed ID: 16634011
    [No Abstract]   [Full Text] [Related]  

  • 10. Frequency of TERT promoter mutations in human cancers.
    Vinagre J; Almeida A; Pópulo H; Batista R; Lyra J; Pinto V; Coelho R; Celestino R; Prazeres H; Lima L; Melo M; da Rocha AG; Preto A; Castro P; Castro L; Pardal F; Lopes JM; Santos LL; Reis RM; Cameselle-Teijeiro J; Sobrinho-Simões M; Lima J; Máximo V; Soares P
    Nat Commun; 2013; 4():2185. PubMed ID: 23887589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective expression of HRK is associated with promoter methylation in primary central nervous system lymphomas.
    Nakamura M; Ishida E; Shimada K; Nakase H; Sakaki T; Konishi N
    Oncology; 2006; 70(3):212-21. PubMed ID: 16809940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system.
    Koelsche C; Sahm F; Capper D; Reuss D; Sturm D; Jones DT; Kool M; Northcott PA; Wiestler B; Böhmer K; Meyer J; Mawrin C; Hartmann C; Mittelbronn M; Platten M; Brokinkel B; Seiz M; Herold-Mende C; Unterberg A; Schittenhelm J; Weller M; Pfister S; Wick W; Korshunov A; von Deimling A
    Acta Neuropathol; 2013 Dec; 126(6):907-15. PubMed ID: 24154961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase reverse transcriptase gene promoter mutations help discern the origin of urogenital tumors: a genomic and molecular study.
    Wu S; Huang P; Li C; Huang Y; Li X; Wang Y; Chen C; Lv Z; Tang A; Sun X; Lu J; Li W; Zhou J; Gui Y; Zhou F; Wang D; Cai Z
    Eur Urol; 2014 Feb; 65(2):274-7. PubMed ID: 24215939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary CNS lymphoma.
    Hochberg FH; Baehring JM; Hochberg EP
    Nat Clin Pract Neurol; 2007 Jan; 3(1):24-35. PubMed ID: 17205072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of TERT Promoter Mutations in Prostate Cancer.
    Stoehr R; Taubert H; Zinnall U; Giedl J; Gaisa NT; Burger M; Ruemmele P; Hurst CD; Knowles MA; Wullich B; Hartmann A
    Pathobiology; 2015; 82(2):53-7. PubMed ID: 25997473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical appearance of a primary central nervous system lymphoma.
    Trendelenburg G; Zimmer C; Forschler A; Stadelmann C; Zschenderlein R
    Arch Neurol; 2006 Jun; 63(6):908-9. PubMed ID: 16769876
    [No Abstract]   [Full Text] [Related]  

  • 18. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas.
    Brunn A; Nagel I; Montesinos-Rongen M; Klapper W; Vater I; Paulus W; Hans V; Blümcke I; Weis J; Siebert R; Deckert M
    Acta Neuropathol; 2013 Oct; 126(4):603-5. PubMed ID: 24061549
    [No Abstract]   [Full Text] [Related]  

  • 20. Absence of CXCR4 mutations but high incidence of double mutant in CD79A/B and MYD88 in primary central nervous system lymphoma.
    Poulain S; Boyle EM; Tricot S; Demarquette H; Doye E; Roumier C; Duthilleul P; Preudhomme C; Maurage CA; Morschhauser F
    Br J Haematol; 2015 Jul; 170(2):285-7. PubMed ID: 25643939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.